2019-04-28 16:00Financial Performance - The company reported a total revenue of RMB 1,247,201,704 for the year 2018, marking a year-on-year increase of 15%[6]. - The company's operating revenue for 2018 was CNY 4,814,965,143.62, representing a 69.34% increase compared to the previous year[26]. - Net profit attributable to shareholders for 2018 was CNY 616,193,781.39, a significant increase of 213.33% year-over-year[26]. - The net profit after deducting non-recurring gains and losses reached CNY 420,508,823.39, marking a 929.45% increase compared to the previous year[26]. - Basic earnings per share for 2018 was CNY 0.4941, up 213.32% from CNY 0.1577 in 2017[28]. - Total assets at the end of 2018 were CNY 13,655,079,889.35, a decrease of 3.29% from the previous year[28]. - The weighted average return on equity for 2018 was 9.14%, an increase of 6.69% compared to 2017[28]. - The company's net profit attributable to ordinary shareholders for 2018 was 616,193,781.39 yuan, with a dividend payout ratio of 20.24%[172]. - Cash dividend amount is CNY 124,720,170.40, representing 6.43% of the distributable profit of CNY 1,940,094,058.22[173]. Investment and Acquisitions - The company completed a cash acquisition of 100% equity in Shenzhen Duople Industrial Development Co., Ltd., which required retrospective adjustments to the financial statements[31]. - The company completed the acquisition of 100% of Duopule, enhancing its capabilities in the enoxaparin raw material and formulation sectors[46]. - The company has committed to an investment project for the annual production of 50 trillion units of heparin sodium raw materials, with a total investment of CNY 29,312.3 million[119]. - The company has invested CNY 71,529.57 million in the heparin project as of December 31, 2016, indicating a significant investment commitment[122]. - The company completed the acquisition of Shenzhen Duople Industrial Development Co., Ltd. shares amounted to CNY 120,000 million, with a near-complete investment of CNY 119,999.99 million[123]. - The company has reported a realized benefit of CNY 36,230.19 million from its investment activities during the reporting period[123]. Market Expansion and Product Development - The company is focusing on expanding its market presence and enhancing its product portfolio through strategic acquisitions and partnerships[6]. - Future outlook indicates a commitment to research and development, particularly in new drug formulations and technologies[6]. - The company is exploring international markets, particularly in Europe and North America, to diversify its revenue streams[6]. - The company has established a pipeline of innovative drugs through investments, acquisitions, and collaborations, with several candidates in preclinical and clinical stages[160]. - The company aims to become a global leader in the heparin industry while expanding its innovative drug pipeline focused on oncology and cardiovascular diseases[151]. Research and Development - The company is actively transitioning towards innovative drug development, establishing a pipeline of products in various clinical trial stages, which supports future business growth[51]. - The company has completed two out of six R&D projects and holds 11 pending patents and 6 authorized patents[62]. - Research and development expenses increased by 99.76% to CNY 186,852,629.89 due to the integration of Junshentai and increased R&D costs[87]. - The number of R&D personnel increased by 52.94% to 208, with R&D investment amounting to CNY 189,608,536.36, which is 3.94% of operating revenue[93]. Risk Management - The company has identified key risks for future development and outlined corresponding mitigation strategies in its annual report[6]. - The company is exposed to foreign exchange risks due to significant exports and overseas subsidiaries, and it employs financial instruments to manage these risks[164]. - The company is committed to increasing quality control measures to mitigate product quality risks associated with complex production processes[157]. Operational Efficiency - The company plans to enhance its production capacity to meet growing demand, with an investment of RMB 200 million in new facilities[6]. - The company has developed a comprehensive quality management system in compliance with GMP standards, ensuring product quality stability and safety[47]. - The management transformation includes process optimization and the implementation of information technology to enhance operational efficiency[63]. Customer Engagement and Sales - User data shows a significant increase in customer engagement, with a 20% rise in active users compared to the previous year[6]. - The sales of raw materials amounted to ¥3,030,781,231.01, representing 62.95% of total revenue, with a growth rate of 57.59% compared to the previous year[69]. - International sales accounted for ¥4,351,289,560.36, which is 90.37% of total revenue, reflecting a growth of 78.53% year-on-year[69]. Dividend Policy - The profit distribution plan approved by the board includes a cash dividend of RMB 1.00 per 10 shares, totaling RMB 124,720,170.40[6]. - The cash dividend distribution plan complies with the requirement that cash dividends should account for at least 40% of the profit distribution total[173]. - The company’s cash dividend policy has been consistent, with no changes in the past three years, ensuring shareholder interests are protected[166].